Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.46 |
| ▸ | MGLL | Q99685 | 7/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.34 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25324446 | 0.83 | MGLL (0.51) | MGLLRBP4 | |
| SCHEMBL25326498 | 0.82 | PDE2A (0.38) | MGLLPDE2AENPP2ATXN2 | |
| SCHEMBL25325656 | 0.81 | MGLL (0.44) | MGLLPDE2AENPP2ATXN2 | |
| SCHEMBL25324545 | 0.81 | ENPP2 (0.41) | MGLLPDE2AENPP2ATXN2 | |
| SCHEMBL25325835 | 0.80 | MGLL (0.37) | MGLLPDE2AENPP2ATXN2 | |
| SCHEMBL25325783 | 0.79 | PDE2A (0.41) | MGLLPDE2AENPP2ATXN2 | |
| SCHEMBL25326927 | 0.79 | SLC6A4 (0.40) | MGLLPDE2AENPP2ATXN2 | |
| SCHEMBL25322265 | 0.78 | POLB (0.39) | MGLLPDE2AENPP2ATXN2 | |
| SCHEMBL25328254 | 0.77 | MGLL (0.42) | MGLL | |
| SCHEMBL25326455 | 0.77 | MGLL (0.47) | MGLLPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | claimed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | claimed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | CHRNA7 703/4885MGLL 3523/4885PDE2A 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.